Immuno-Oncology | Specialty

Future Directions in Treating HNSCC

July 7th 2017

Emerging Agents to Treat HNSCC

July 7th 2017

Predictive Biomarkers in HNSCC

July 7th 2017

Patient Selection in Treating HNSCC

July 7th 2017

Nivolumab in HNSCC

July 7th 2017

Pembrolizumab in HNSCC

July 7th 2017

Checkpoint Inhibitors for Recurrent HNSCC

July 7th 2017

Checkpoint Inhibitors in HNSCC

July 7th 2017

Dr. Daud on the Combinations of Immunotherapy for Melanoma

July 6th 2017

Adil Daud, MD, a clinical professor, Department of Medicine at University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses potential combinations of immunotherapy for the treatment of patients with melanoma.

Dr. Garon on Future of Immunotherapy in NSCLC

July 6th 2017

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the future of immunotherapy in the paradigm of non–small cell lung cancer (NSCLC).

FDA Places Clinical Hold on 3 Pembrolizumab Myeloma Trials

July 6th 2017

The FDA has placed a clinical hold on the phase III KEYNOTE-183 and KEYNOTE-185 pembrolizumab (Keytruda) trials and ordered the discontinuation of the lenalidomide/dexamethasone/pembrolizumab arm of the KEYNOTE-023 trial in patients with multiple myeloma.

Expert Discusses Dramatic Impact of Immunotherapy on NSCLC Paradigm

July 6th 2017

Melissa Johnson, MD, discusses the impact of immunotherapy for patients with non-small cell lung cancer—those with both high and low levels of PD-L1 expression—and how the treatment and the role of PD-L1 will continue to progress in the coming years.

Dr. Rini on Adjuvant Immunotherapy in Renal Cell Carcinoma

July 6th 2017

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the potential of immunotherapy as an adjuvant treatment for patients with renal cell carcinoma (RCC).

Pembrolizumab Demonstrates Long-Term OS Benefit in Advanced Melanoma

July 6th 2017

Pembrolizumab (Keytruda) provides a long-term survival benefit in both ipilimumab-naïve and ipilimumab-treated patients with advanced melanoma.

Adjuvant Nivolumab Improves RFS Versus Ipilimumab in Melanoma

July 5th 2017

Adjuvant nivolumab (Opdivo) extended recurrence-free survival compared with adjuvant ipilimumab (Yervoy) in patients with advanced melanoma enrolled in the phase III CheckMate-238 trial.

Dr. Lenz Discusses Immunotherapy in Gastrointestinal Cancers

July 1st 2017

Heinz-Josef Lenz, MD, FACP, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses immunotherapy in gastrointestinal cancers.

Novel Bispecific Antibody Effective for Heavily Pretreated mCRC

July 1st 2017

CEA-TCB showed a favorable safety profile and promising efficacy in patients with heavily-pretreated microsatellite stable metastatic colorectal cancer, with enhanced efficacy when combined with atezolizumab.

PD-1/PD-L1 Inhibitors Arrive in Merkel Cell Carcinoma

July 1st 2017

Immune checkpoint inhibitors against PD-1 and PD-L1 are showing promise across clinical trials for patients with Merkel cell carcinoma.

Advanced Age Presents No Barrier to Successful Nivolumab Treatment in HCC

June 30th 2017

Durable responses and improved long-term survival were demonstrated with nivolumab (Opdivo) that were not altered by the age of patients with advanced hepatocellular carcinoma across all age groups of patients participating in the CheckMate 040 trial.

Expert Discusses IDO/PD-1 and Other Emerging Combos in Melanoma

June 30th 2017

Adil Daud, MD, discusses combination regimens and biomarkers being explored to advance immunotherapy in the field of melanoma.